News

NICHE-2: No disease recurrences after five years of follow-up

ESMO 2026: Perioperative apalutamide in high-risk localised or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

Major study identifies potential new treatment targets for the most common type of bowel cancer

ESMO 2026: Novel cancer immunotherapy drug generates promising clinical trial results

ESMO 2026: Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer

ESMO 2026: Immunotherapy combo extends survival for patients with aggressive small cell lung cancer

ESMO 2026: Patients with a form of advanced lung cancer lived 56% longer without their disease progressing after receiving radiotherapy in addition to standard treatment

ESMO 2026: Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy

New study identifies potential new treatment targets for the most common type of bowel cancer

FDA grants traditional approval for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic c with updated indication

Cancer cells killed with their own carbon monoxide

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death